HLA-G highly expressed in renal cancer cells specifically impaired the anti-tumor function of CD8+ILT2+PD1-T cells, rather than CD8+ILT2−PBMC or CD8+PD-1+T cells [222], hinting that blockade of HLA-G might be applicable to the patients who failed to respond to anti-PD-1/PD-L1 therapy, as a complement to existing immunotherapy regimens. This evidence concerns the gene LILRB1 and neoplasm.